A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...